Journal Article Summary
The article investigates the metabolic changes in patients with acute myeloid leukemia (AML) who are undergoing a low-toxicity treatment regimen that includes all-trans retinoic acid (ATRA) and valproic acid, combined with low-dose chemotherapy. This topic is significant because AML is a highly aggressive cancer, particularly affecting older adults who may not tolerate intensive therapies. Understanding how these treatments affect metabolism could provide insights into their effectiveness and help identify which patients are likely to respond to therapy.
The study involved 44 elderly or unfit AML patients, with a median age of 76.4 years, who were treated with ATRA, valproic acid, and low-dose cytotoxic drugs. Researchers conducted untargeted serum metabolomic profiling, identifying 886 metabolites in the patients' blood samples. They found that while there were some differences in metabolite levels between responders and non-responders to treatment, these were not highly significant. However, patients with rapidly progressive disease exhibited notable alterations in lipid metabolism, suggesting that metabolic profiling could help distinguish between different disease aggressiveness levels.
Limitations of the study include the small sample size and the complexity of analyzing metabolomic data, which can lead to false positives. Patients and caregivers should be aware that while metabolic profiling may offer insights into treatment responses, it is still an emerging field and not yet a standard practice. It is essential for readers to discuss any concerns or questions about AML treatments and their metabolic implications with a healthcare professional, especially considering the potential for variations in treatment effectiveness among individuals.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Grønningsæter Ida Sofie, Fredly Hanne Kristin, Gjertsen Bjørn Tore, Hatfield Kimberley Joanne, Bruserud Øystein. Systemic Metabolomic Profiling of Acute Myeloid Leukemia Patients before and During Disease-Stabilizing Treatment Based on All-Trans Retinoic Acid, Valproic Acid, and Low-Dose Chemotherapy. Cells 2019. DOI: 10.3390/cells8101229. PMID: 31658693. PMCID: PMC6829623.
Featured Pill Pals Product
Divalproex Sodium 125 mg Delayed Release Tablets --- Generic For Depakote --- Sun
Divalproex Sodium 125 mg Delayed Release Tablets — Generic For Depakote — Sun is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
